Navigation Links
Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
Date:1/17/2012

HOBOKEN, N.J. and PHILADELPHIA, Jan. 17, 2012 /PRNewswire/ -- Niiki Pharma Inc. announced today that it has completed the dose escalation portion of the Phase I clinical trial of its lead product, NKP-1339. NKP-1339 is a first-in-class small molecule that down-regulates GRP78, a key tumor survival and anti-apoptosis factor.

The NKP-1339 single agent dose escalation Phase I trial was conducted in patients with advanced solid tumors resistant to multiple, standard therapies. NKP-1339 was administered intravenously once weekly for 3 weeks followed by one week of no treatment. Thirty-four patients were treated, of which 30 were evaluable for dose determination. The NKP-1339 Phase I trial is being led by Dr. Daniel Von Hoff, Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare in partnership with Translational Genomics Institute, and Dr. Howard Burris, at the Sarah Cannon Research Institute.

The NKP-1339 dose limiting toxicity was grade 2-3 nausea and grade 1-2 reversible renal insufficiency. At the recommended Phase II dose, NKP-1339 treatment was generally well tolerated and had manageable side effects. The most common drug-related side effects were grade 1 nausea, grade 1-2 vomiting and grade 1-2 fatigue. Infusional fever and chills were noted but prevented with steroid premedication.

"We reached our goal to determine the dose of NKP-1339 to take forward in future trials. Many toxicities commonly associated with other anticancer drugs, such as neutropenia, hepatotoxicity, neuropathy, rash, mucositis, diarrhea and alopecia, have not been seen to date," said Dr. Burris.

Anti-tumor activity, demonstrated by disease stability and/or tumor regression for 12-88+ weeks, was noted in patients with neuroendocrine tumors (NET), non-small cell lung cancer, sarcoma, colorectal and cancer of unknown primary. Three patients continue to receive NKP-1339 therapy on study.

"The preliminary read of NKP-1339 anti-tumor activity
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
2. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
3. Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... , , , ... Claims and Clearinghouse Service in the 2009 Top 20 ... RealMed is a dynamic revenue cycle management solution providing advanced, ... payers. KLAS is an independent research firm specializing in ...
... ... today announced a series of flexible financing solutions ... and meet deadlines defined within the HITECH provision of the ... interest terms for qualified customers, the solutions enable organizations to ...
Cached Medicine Technology:RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
(Date:4/24/2014)... first flu pandemic in the 21st century. The virus ... 50 people in the country. Since 2011 the pH1N1 ... , Infections with influenza pH1N1 virus vary from ... recommended Tamiflu for treatment of patients with severe or ... it targets viral proteins which mutate quickly and the ...
(Date:4/23/2014)... clinical trials for a new experimental drug to ... Patients treated with CPX-351, a combination of the ... responses than patients treated with the standard drug ... is an aggressive blood cancer with very low ... explained Jeffrey Lancet, M.D., senior member of the ...
(Date:4/23/2014)... high-energy particles, simulating conditions astronauts would face on a ... slower reaction times, even when the radiation exposure is ... which affected a large subset, but far from ... to protein changes in the brain, the scientists say. ... suggest it may be possible to develop a biological ...
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... Satori World Medical, ... certain providers of Sistemas Medicos Nacionales, S.A. de C.V. (SIMNSA) to its network in Mexico. ... San Diego, CA ... in the emerging medical tourism industry, announced the addition of certain providers of Sistemas Medicos ...
... 14 Continuing its efforts to educate, inform, and ... not-for-profit patient-focused organization, is hosting its 25-minute live call-in ... on Monday, October 19, 2009 at 6:00 PM on ... a frank discussion regarding Retail Health Clinics with Erin ...
... HARBIN, China, Oct. 14 /PRNewswire-Asia-FirstCall/-- SOKO Fitness ... of fitness centers,and beauty salons and spas in Northeast China, ... Officer Yu Xia, and,Corporate Secretary Jiang Judy will host a ... 9 am EDT on Oct. 16. , , ...
... of altruism , WEDNESDAY, Oct. 14 (HealthDay News) ... they,re not likely to offer help voluntarily, say researchers ... Japanese research team studied six pairs of chimpanzees (three ... designed to find out whether a chimpanzee would give ...
... ... feature the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at the 23rd ... , ... Arbor, Mich. (PRWEB) -- Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, ...
... BNVI ) announced today the appointment of Dr. Debu ... Program at the University Southern California, to the company,s Medical ... researcher in the area of breast cancer. , "We ... in the area of breast cancer join our Medical Advisory ...
Cached Medicine News:Health News:SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options 2Health News:Retail Health Clinics - The Real Story 2Health News:SOKO Fitness & Spa Group, Inc. to Hold FY 2010 Q1 Earnings Call on Oct. 16 2Health News:SOKO Fitness & Spa Group, Inc. to Hold FY 2010 Q1 Earnings Call on Oct. 16 3Health News:If You Want Help From a Chimp, You'll Have to Ask 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 3Health News:Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board 2Health News:Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board 3
Midstream Catch Kits...
... a handheld, noninvasive ultrasound instrument that measures ... so any staff member can scan patients ... from exams and print BVI 6100 exam ... log on to ScanPoint®, Diagnostic Ultrasound's innovative ...
... The Mobile BladderScan® BVI 6400 calculates ... ultrasound technology. V-MODE® ultrasound is accurate, ... seconds, the BladderScan® measures ultrasonic reflections ... planes, creates a 3-dimensional image of ...
... EXP Injectable Bulking Agent is ... suspended in a water-based carrier ... Agent is indicated for the ... stress urinary incontinence due to ...
Medicine Products: